Gene-by-Gene, Inc. was one of the first direct-to-consumer (DTC) genetic diagnostics companies to announce that it would offer BRCA1/BRCA2 testing after the Supreme Court’s decision last June that certain of Myriad Genetics’ claims (those that encompassed isolated genomic DNA) were invalid for reciting patent-ineligible subject matter. And Gene-by-Gene was one of the first DTC genetic diagnostic companies sued by Myriad for offering such testing followed by lawsuits against several other companies offering or threatening to offer Myriad’s BRCA tests.
Now, Gene-by-Gene has become the first DTC genetic diagnostic company to settle with Myriad, in what can only be characterized as complete victory for the patentee.
Read the full, original story: Gene-by-Gene Cries Uncle, Settles with Myriad Genetics
